The emergence of mRNA therapeutics including the development of new vaccines and gene therapies has created a market constraint on access to critical raw materials, scientific and technical expertise. Thermo Fisher Scientific knows nucleic acids and pharmaceutical services and has worked to integrate our capabilities across the operational value chain to enable the development and commercialization of mRNA therapeutics.
Thermo Fisher Scientific has over a decade of experience in cGMP manufacturing of raw materials to support the emerging mRNA market. TheraPure mRNA synthesis enzymes offering spans across the entire mRNA manufacturing value chain from template generation and linearization all the way to RNA purification. Our experience and access to raw materials means we have the resources needed to plan and manufacture according to your needs.
Thermo Fisher Scientific Patheon has over 20 years of operational and regulatory experience in complex sterile manufacturing, including quality scrutiny, supply chain, procurement, and technology transfer. We know what it takes to advance mRNA therapeutics to market and can support you along the way.
Our global network of sites with mRNA capabilities includes cGMP manufacture, formulation with liquid nanoparticle (LNP), sterile fill and finish, as well as logistics and supply chain networks. We are well suited to support complex and unique cGMP mRNA manufacturing needs and scale-up.
Access our expertise for your mRNA advanced therapeutics